Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 9/2016

Open Access 01-09-2016 | Original Article

Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients

Authors: Said Farschtschi, Su-Jin Park, Birgit Sawitzki, Su-Jun Oh, Lan Kluwe, Victor F. Mautner, Andreas Kurtz

Published in: Cancer Immunology, Immunotherapy | Issue 9/2016

Login to get access

Abstract

Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome caused by mutations of the NF1 gene and resulting dysregulation of the Ras-pathway. In addition to peripheral nerve tumors, affected tissues include the musculoskeletal and cardiovascular system. The immune system has recently been suggested as a possible modulator NF1-related phenotypes. Therefore, we determined the immune phenotype in NF1 patients and investigated its relationship with the phenotypic severity of NF1-related tumor manifestations. We quantified global leukocytes and lymphocyte subpopulations of peripheral blood from 37 NF1 patients and 21 healthy controls by flow cytometry. To associate immune phenotype with tumor phenotype, all NF1 patients underwent whole-body magnetic resonance imaging and total internal tumor volume was calculated. The immunophenotypes were compared among four NF1 groups with different total internal tumor burdens and between NF1 patients and non-NF1 subjects. We found that NF1 patients show a generalized lymphopenia. Closer analysis revealed that the CD8+/CD27 and CD8+/CD57+ effector T cell fractions strongly increase in NF1 patients with low tumor load and decrease to levels below control in patients with high tumor load. Moreover, increased production of IL2, IFN-γ and TNF-α was found in T cells of NF1 patients upon phorbol-12-myristate acetate (PMA) stimulation compared to healthy controls. The data indicate that decreasing CD8+/CD57+ and CD27 T cell fractions correspond to increasing tumor load in NF1 patients, potentially making these populations useful marker for internal tumor burden.
Literature
1.
go back to reference Huson SM, Compston DA, Harper PS (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet 26:712–721CrossRefPubMedPubMedCentral Huson SM, Compston DA, Harper PS (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet 26:712–721CrossRefPubMedPubMedCentral
2.
go back to reference Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (1999) Neurofibromatosis. Phenotype, Natural History and Pathogenesis. The Johns Hopkins University Press, Baltimore, pp 110–118 Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (1999) Neurofibromatosis. Phenotype, Natural History and Pathogenesis. The Johns Hopkins University Press, Baltimore, pp 110–118
4.
go back to reference Larizza L, Gervasini C, Natacci F, Riva P (2009) Developmental abnormalities and cancer predisposition in neurofibromatosis type 1. Curr Mol Med 9(5):634–653CrossRefPubMed Larizza L, Gervasini C, Natacci F, Riva P (2009) Developmental abnormalities and cancer predisposition in neurofibromatosis type 1. Curr Mol Med 9(5):634–653CrossRefPubMed
6.
7.
go back to reference Nürnberger M, Moll I (1994) Semiquantitative aspects of mast cells in normal skin and in neurofibromas of neurofibromatosis types 1 and 5. Dermatology 188(4):296–299CrossRefPubMed Nürnberger M, Moll I (1994) Semiquantitative aspects of mast cells in normal skin and in neurofibromas of neurofibromatosis types 1 and 5. Dermatology 188(4):296–299CrossRefPubMed
8.
go back to reference Tucker T, Riccardi VM, Sutcliffe M, Vielkind J, Wechsler J, Wolkenstein P et al (2011) Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1. J Histochem Cytochem 59:584–590CrossRefPubMedPubMedCentral Tucker T, Riccardi VM, Sutcliffe M, Vielkind J, Wechsler J, Wolkenstein P et al (2011) Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1. J Histochem Cytochem 59:584–590CrossRefPubMedPubMedCentral
9.
go back to reference Riccardi VM (1981) Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser 17(2):129–145PubMed Riccardi VM (1981) Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser 17(2):129–145PubMed
10.
go back to reference Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330(9):597–601CrossRefPubMed Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330(9):597–601CrossRefPubMed
11.
go back to reference Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM (1996) Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood 88(11):4314–4320PubMed Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM (1996) Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood 88(11):4314–4320PubMed
13.
15.
go back to reference Staser K, Park SJ, Rhodes SD, Zeng Y, He YZ, Shew MA et al (2013) Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. J Clin Invest 123(1):329–334CrossRefPubMed Staser K, Park SJ, Rhodes SD, Zeng Y, He YZ, Shew MA et al (2013) Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. J Clin Invest 123(1):329–334CrossRefPubMed
16.
go back to reference Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM et al (2010) Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest 120:859–870CrossRefPubMedPubMedCentral Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM et al (2010) Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest 120:859–870CrossRefPubMedPubMedCentral
17.
go back to reference Stansfield BK, Bessler WK, Mali R, Mund JA, Downing B, Li F et al (2013) Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway. Hum Mol Genet 22(5):977–988CrossRefPubMed Stansfield BK, Bessler WK, Mali R, Mund JA, Downing B, Li F et al (2013) Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway. Hum Mol Genet 22(5):977–988CrossRefPubMed
18.
go back to reference Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, Guise TA, Yang FC (2011) The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One 6(9):e24917CrossRefPubMedPubMedCentral Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, Guise TA, Yang FC (2011) The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One 6(9):e24917CrossRefPubMedPubMedCentral
19.
go back to reference Simmons GW et al (2011) Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 70(1):51–62CrossRefPubMedPubMedCentral Simmons GW et al (2011) Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 70(1):51–62CrossRefPubMedPubMedCentral
20.
go back to reference Ingram DA, Zhang L, McCarthy J, Wenning MJ, Fisher L, Yang FC, Clapp DW, Kapur R (2002) Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood 100(10):3656–3662CrossRefPubMed Ingram DA, Zhang L, McCarthy J, Wenning MJ, Fisher L, Yang FC, Clapp DW, Kapur R (2002) Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood 100(10):3656–3662CrossRefPubMed
21.
go back to reference Oliver JA, Lapinski PE, Lubeck BA, Turner JS, Parada LF, Zhu Y, King PD (2013) The Ras GTPase-activating protein neurofibromin 1 promotes the positive selection of thymocytes. Mol Immunol 55(3–4):292–302CrossRefPubMedPubMedCentral Oliver JA, Lapinski PE, Lubeck BA, Turner JS, Parada LF, Zhu Y, King PD (2013) The Ras GTPase-activating protein neurofibromin 1 promotes the positive selection of thymocytes. Mol Immunol 55(3–4):292–302CrossRefPubMedPubMedCentral
22.
go back to reference Reuss DE, Mucha J, Holtkamp N, Müller U, Berlien HP, Mautner VF et al (2013) Functional MHC Class II Is upregulated in neurofibromin-deficient schwann cells. J Invest Dermatol 133(5):1372–1375CrossRefPubMed Reuss DE, Mucha J, Holtkamp N, Müller U, Berlien HP, Mautner VF et al (2013) Functional MHC Class II Is upregulated in neurofibromin-deficient schwann cells. J Invest Dermatol 133(5):1372–1375CrossRefPubMed
23.
go back to reference Park SJ, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A (2013) Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve sheath tumors. BMC Med 11:109CrossRefPubMedPubMedCentral Park SJ, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A (2013) Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve sheath tumors. BMC Med 11:109CrossRefPubMedPubMedCentral
24.
go back to reference Mashour GA, Driever PH, Hartmann M, Drissel SN, Zhang T, Scharf B et al (2004) Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin Cancer Res 10:5677–5683CrossRefPubMed Mashour GA, Driever PH, Hartmann M, Drissel SN, Zhang T, Scharf B et al (2004) Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin Cancer Res 10:5677–5683CrossRefPubMed
25.
go back to reference Lévy P, Bièche I, Leroy K, Parfait B, Wechsler J, Laurendeau I et al (2004) Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 10:3763–3771CrossRefPubMed Lévy P, Bièche I, Leroy K, Parfait B, Wechsler J, Laurendeau I et al (2004) Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 10:3763–3771CrossRefPubMed
26.
go back to reference Focosi D, Bestagno M, Burrone O, Petrini M (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87(1):107–116CrossRefPubMed Focosi D, Bestagno M, Burrone O, Petrini M (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87(1):107–116CrossRefPubMed
27.
go back to reference Ferner RE, Gutmann DH (2013) Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 115:939–955CrossRefPubMed Ferner RE, Gutmann DH (2013) Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 115:939–955CrossRefPubMed
28.
go back to reference Hematology: Clinical Principles and Applications. By Bernadette F. Rodak, George A. Fritsma, Elaine Keohane, ELSEVIER Saunters. 3251 Riverport Ln, St Louis, Missouri 63043, (2012) ISBN 978-1-4377-0692-5 Hematology: Clinical Principles and Applications. By Bernadette F. Rodak, George A. Fritsma, Elaine Keohane, ELSEVIER Saunters. 3251 Riverport Ln, St Louis, Missouri 63043, (2012) ISBN 978-1-4377-0692-5
29.
go back to reference Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S et al (2012) Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 7(4):e35711CrossRefPubMedPubMedCentral Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S et al (2012) Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 7(4):e35711CrossRefPubMedPubMedCentral
30.
go back to reference Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R et al (2008) Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 10(4):593–598CrossRefPubMedPubMedCentral Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R et al (2008) Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 10(4):593–598CrossRefPubMedPubMedCentral
Metadata
Title
Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients
Authors
Said Farschtschi
Su-Jin Park
Birgit Sawitzki
Su-Jun Oh
Lan Kluwe
Victor F. Mautner
Andreas Kurtz
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 9/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1871-0

Other articles of this Issue 9/2016

Cancer Immunology, Immunotherapy 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine